title: Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA.
abstract: On the basis of the functional model of the basal ganglia developed in the 1980s and the neuropathological findings in Huntington's disease (HD), changes in the neuronal activity of the basal ganglia have previously been proposed to explain the abnormal movements observed in this pathology. In particular, it has been stated that the neurodegenerative process affecting the basal ganglia in the disease should provoke a hypoactivity in the internal segment of the pallidum (GPi) that could explain choreic movements observed in the disease. To test this functional hypothesis, we performed an in situ hybridization study on control and HD brains postmortem, taking cytochrome oxidase subunit I (COI) mRNAs expression as index of neuronal activity. As most of the HD patients studied were under chronic neuroleptic (NL) treatment, we also studied the brains of non-HD patients under chronic NL treatment. Our results show that in HD brain the number of neurons expressing COI mRNA tends to be lower in the striatum, GPe and GPi, suggesting a severe involvement of these structures during the neurodegenerative process. Moreover, COI mRNA level of expression was markedly reduced within neurons of the putamen and GPe. Surprisingly, COI mRNA expression was not modified in the GPi in HD brains compared with controls. This paradoxical result in the GPi may be explained by the antagonistic effect of GPe hypoactivity and the degenerative process involving neurons of GPi. Our results indicate that the functional modifications, and consequently the pathophysiology of abnormal movements, observed in HD basal ganglia are more complex than expected from the currently accepted model of the basal ganglia organization.
authors.affiliation: INSERM U289, Hôpital de la Salpêtrière, Paris, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gourfinkel-An
authors.forename: Miquel
authors.initials: M
authors.lastname: Vila
authors.forename: Baptiste
authors.initials: B
authors.lastname: Faucheux
authors.forename: Charles
authors.initials: C
authors.lastname: Duyckaerts
authors.forename: François
authors.initials: F
authors.lastname: Viallet
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Hauw
authors.forename: Alexis
authors.initials: A
authors.lastname: Brice
authors.forename: Yves
authors.initials: Y
authors.lastname: Agid
authors.forename: Etienne C
authors.initials: EC
authors.lastname: Hirsch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001479:Basal Ganglia / Q000201:enzymology*; D003576:Electron Transport Complex IV / Q000235:genetics* / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy / Q000378:metabolism*; D017403:In Situ Hybridization; D008875:Middle Aged; D009474:Neurons / Q000201:enzymology; D012333:RNA, Messenger
chemical_list: D014150:Antipsychotic Agents; D012333:RNA, Messenger; D003576:Electron Transport Complex IV